X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs WOCKHARDT LTD. - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD WOCKHARDT LTD. ORCHID PHARMA LTD/
WOCKHARDT LTD.
 
P/E (TTM) x -0.5 -15.9 - View Chart
P/BV x 0.4 2.6 14.6% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ORCHID PHARMA LTD   WOCKHARDT LTD.
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
WOCKHARDT LTD.
Mar-17
ORCHID PHARMA LTD/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1941,129 17.2%   
Low Rs35627 5.6%   
Sales per share (Unadj.) Rs276.5363.1 76.1%  
Earnings per share (Unadj.) Rs-79.2-20.4 387.4%  
Cash flow per share (Unadj.) Rs-43.5-7.0 622.9%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs53.9301.8 17.9%  
Shares outstanding (eoy) m70.45110.55 63.7%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x0.42.4 17.1%   
Avg P/E ratio x-1.4-42.9 3.4%  
P/CF ratio (eoy) x-2.6-125.9 2.1%  
Price / Book Value ratio x2.12.9 73.0%  
Dividend payout %0-48.9 0.0%   
Avg Mkt Cap Rs m8,06797,063 8.3%   
No. of employees `0002.86.8 41.4%   
Total wages/salary Rs m2,5279,665 26.1%   
Avg. sales/employee Rs Th6,956.15,931.8 117.3%   
Avg. wages/employee Rs Th902.51,428.1 63.2%   
Avg. net profit/employee Rs Th-1,993.0-334.0 596.7%   
INCOME DATA
Net Sales Rs m19,47740,146 48.5%  
Other income Rs m4071,143 35.6%   
Total revenues Rs m19,88441,289 48.2%   
Gross profit Rs m1,103128 861.4%  
Depreciation Rs m2,5191,489 169.2%   
Interest Rs m5,2272,253 232.0%   
Profit before tax Rs m-6,236-2,472 252.3%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125-211 59.3%   
Profit after tax Rs m-5,580-2,260 246.9%  
Gross profit margin %5.70.3 1,775.5%  
Effective tax rate %2.08.5 23.5%   
Net profit margin %-28.7-5.6 508.9%  
BALANCE SHEET DATA
Current assets Rs m11,01446,160 23.9%   
Current liabilities Rs m32,06019,258 166.5%   
Net working cap to sales %-108.167.0 -161.3%  
Current ratio x0.32.4 14.3%  
Inventory Days Days95101 94.2%  
Debtors Days Days3494 35.7%  
Net fixed assets Rs m29,44040,165 73.3%   
Share capital Rs m705553 127.5%   
"Free" reserves Rs m2,04332,814 6.2%   
Net worth Rs m3,80033,367 11.4%   
Long term debt Rs m9,01831,903 28.3%   
Total assets Rs m46,51089,687 51.9%  
Interest coverage x-0.2-0.1 198.8%   
Debt to equity ratio x2.41.0 248.2%  
Sales to assets ratio x0.40.4 93.6%   
Return on assets %-0.80 8,852.7%  
Return on equity %-146.9-6.8 2,167.8%  
Return on capital %-3.7-0.3 1,114.1%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,5139,121 82.4%   
Fx outflow Rs m5,6492,133 264.8%   
Net fx Rs m1,8656,988 26.7%   
CASH FLOW
From Operations Rs m1,682-2,695 -62.4%  
From Investments Rs m-9,860-6,863 143.7%  
From Financial Activity Rs m6,64412,545 53.0%  
Net Cashflow Rs m-1,5353,010 -51.0%  

Share Holding

Indian Promoters % 32.3 74.5 43.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 2.3 200.0%  
FIIs % 3.3 7.7 42.9%  
ADR/GDR % 4.6 0.1 4,600.0%  
Free float % 55.3 15.4 359.1%  
Shareholders   84,811 67,757 125.2%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS